PortalPublikationenIxazomib-lenalidomide-dexamethasone in routine clinical prac...

Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma

Standard

Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma. / Hájek, Roman; Minařík, Jiří; Straub, Jan; Pour, Luděk; Jungova, Alexandra; Berdeja, Jesus G; Boccadoro, Mario; Brozova, Lucie; Spencer, Andrew; Rhee, Frits van; Vela-Ojeda, Jorge; Thompson, Michael A; Abonour, Rafat; Chari, Ajai; Cook, Gordon; Costello, Caitlin L; Davies, Faith E; Hungria, Vania Tm; Lee, Hans C; Leleu, Xavier; Puig, Noemi; Rifkin, Robert M; Terpos, Evangelos; Usmani, Saad Z; Weisel, Katja C; Zonder, Jeffrey A; Bařinová, Magda; Kuhn, Matyáš; Šilar, Jiří; Čápková, Lenka; Galvez, Kenny; Lu, Jin; Elliott, Jennifer; Stull, Dawn Marie; Ren, Kaili; Maisnar, Vladimír.

in: FUTURE ONCOL, Jahrgang 17, Nr. 19, 07.2021, S. 2499-2512.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hájek, R, Minařík, J, Straub, J, Pour, L, Jungova, A, Berdeja, JG, Boccadoro, M, Brozova, L, Spencer, A, Rhee, FV, Vela-Ojeda, J, Thompson, MA, Abonour, R, Chari, A, Cook, G, Costello, CL, Davies, FE, Hungria, VT, Lee, HC, Leleu, X, Puig, N, Rifkin, RM, Terpos, E, Usmani, SZ, Weisel, KC, Zonder, JA, Bařinová, M, Kuhn, M, Šilar, J, Čápková, L, Galvez, K, Lu, J, Elliott, J, Stull, DM, Ren, K & Maisnar, V 2021, 'Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma', FUTURE ONCOL, Jg. 17, Nr. 19, S. 2499-2512. https://doi.org/10.2217/fon-2020-1225

APA

Hájek, R., Minařík, J., Straub, J., Pour, L., Jungova, A., Berdeja, J. G., Boccadoro, M., Brozova, L., Spencer, A., Rhee, F. V., Vela-Ojeda, J., Thompson, M. A., Abonour, R., Chari, A., Cook, G., Costello, C. L., Davies, F. E., Hungria, V. T., Lee, H. C., ... Maisnar, V. (2021). Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma. FUTURE ONCOL, 17(19), 2499-2512. https://doi.org/10.2217/fon-2020-1225

Vancouver

Hájek R, Minařík J, Straub J, Pour L, Jungova A, Berdeja JG et al. Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma. FUTURE ONCOL. 2021 Jul;17(19):2499-2512. https://doi.org/10.2217/fon-2020-1225

Bibtex

@article{20fed3095e4b40c5a53ac6c4693d5850,
title = "Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma",
abstract = "Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov).",
author = "Roman H{\'a}jek and Ji{\v r}{\'i} Mina{\v r}{\'i}k and Jan Straub and Lud{\v e}k Pour and Alexandra Jungova and Berdeja, {Jesus G} and Mario Boccadoro and Lucie Brozova and Andrew Spencer and Rhee, {Frits van} and Jorge Vela-Ojeda and Thompson, {Michael A} and Rafat Abonour and Ajai Chari and Gordon Cook and Costello, {Caitlin L} and Davies, {Faith E} and Hungria, {Vania Tm} and Lee, {Hans C} and Xavier Leleu and Noemi Puig and Rifkin, {Robert M} and Evangelos Terpos and Usmani, {Saad Z} and Weisel, {Katja C} and Zonder, {Jeffrey A} and Magda Ba{\v r}inov{\'a} and Maty{\'a}{\v s} Kuhn and Ji{\v r}{\'i} {\v S}ilar and Lenka {\v C}{\'a}pkov{\'a} and Kenny Galvez and Jin Lu and Jennifer Elliott and Stull, {Dawn Marie} and Kaili Ren and Vladim{\'i}r Maisnar",
year = "2021",
month = jul,
doi = "10.2217/fon-2020-1225",
language = "English",
volume = "17",
pages = "2499--2512",
journal = "FUTURE ONCOL",
issn = "1479-6694",
publisher = "Future Medicine Ltd",
number = "19",

}

RIS

TY - JOUR

T1 - Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma

AU - Hájek, Roman

AU - Minařík, Jiří

AU - Straub, Jan

AU - Pour, Luděk

AU - Jungova, Alexandra

AU - Berdeja, Jesus G

AU - Boccadoro, Mario

AU - Brozova, Lucie

AU - Spencer, Andrew

AU - Rhee, Frits van

AU - Vela-Ojeda, Jorge

AU - Thompson, Michael A

AU - Abonour, Rafat

AU - Chari, Ajai

AU - Cook, Gordon

AU - Costello, Caitlin L

AU - Davies, Faith E

AU - Hungria, Vania Tm

AU - Lee, Hans C

AU - Leleu, Xavier

AU - Puig, Noemi

AU - Rifkin, Robert M

AU - Terpos, Evangelos

AU - Usmani, Saad Z

AU - Weisel, Katja C

AU - Zonder, Jeffrey A

AU - Bařinová, Magda

AU - Kuhn, Matyáš

AU - Šilar, Jiří

AU - Čápková, Lenka

AU - Galvez, Kenny

AU - Lu, Jin

AU - Elliott, Jennifer

AU - Stull, Dawn Marie

AU - Ren, Kaili

AU - Maisnar, Vladimír

PY - 2021/7

Y1 - 2021/7

N2 - Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov).

AB - Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov).

U2 - 10.2217/fon-2020-1225

DO - 10.2217/fon-2020-1225

M3 - SCORING: Journal article

C2 - 33769076

VL - 17

SP - 2499

EP - 2512

JO - FUTURE ONCOL

JF - FUTURE ONCOL

SN - 1479-6694

IS - 19

ER -